The inflammatory cytokines interleukin-1␤ and tumor necrosis factor-␣ (TNF-␣) have been identified as mediators of several forms of neurodegeneration in the brain. However, they can produce either deleterious or beneficial effects on neuronal function. We investigated the effects of these cytokines on neuronal death caused by exposure of mouse organotypic hippocampal slice cultures to toxic concentrations of AMPA. Either potentiation of excitotoxicity or neuroprotection was observed, depending on the concentration of the cytokines and the timing of exposure. A relatively high concentration of mouse recombinant TNF-␣ (10 ng/ml) enhanced excitotoxicity when the cultures were simultaneously exposed to AMPA and to this cytokine. Decreasing the concentration of TNF-␣ to 1 ng/ml resulted in neuroprotection against AMPA-induced neuronal death independently on the application protocol. By using TNF-␣ receptor (TNFR) knock-out mice, we demonstrated that the potentiation of AMPA-induced toxicity by TNF-␣ involves TNF receptor-1, whereas the neuroprotective effect is mediated by TNF receptor-2. AMPA exposure was associated with activation and proliferation of microglia as assessed by macrophage antigen-1 and bromodeoxyuridine immunohistochemistry, suggesting a functional recruitment of cytokineproducing cells at sites of neurodegeneration. Together, these findings are relevant for understanding the role of proinflammatory cytokines and microglia activation in acute and chronic excitotoxic conditions.

Brain inflammation is characterized primarily by microglia activation (1). Several stimuli, such as ATP (2), bloodderived factors, or microbial signals (e.g. lipopolysaccharide (LPS)), induce significant morphological changes in microglial cells (3). They become undistinguishable from active macrophages and are able to migrate and proliferate at sites of neuronal injury, where they release both neurotrophic and neurotoxic factors, and inflammatory mediators, such as adhesion molecules, cytokines, and complement molecules among others (4 -6). Consequently, microglia response remains controversial because it can either be beneficial or deleterious depending on the nature, concentration, and time of exposure to the activating stimulus, and the cellular interactions of the targeted tissue. Once the triggering stimulus wanes, microglia participate in the down-modulation of the immune response and in the regulation of their own apoptosis via secretion of antiinflammatory cytokines (3).One of the outcomes of microglia activation is the production of nitric oxide (NO) from the conversion of L-arginine to L-citrulline by Ca 2ϩ -independent inducible nitric oxide synthase (iNOS) 2 (7-9). NO is produced by numerous cells, and it is of particular importance for blood flow regulation, sleepwake cycle, food intake and thermal regulation, immune system function, and neuronal transmission (10). Particularly, in the central nervous system, NO regulation presents itself as an opportunity to intervene in human health. NO can grant neuroprotection through the following mechanisms: reduction of Ca 2ϩ influx, due to S-nitrosylation of caspase 3 and NR1 and NR2 subunits of the N-methyl-D-aspartate receptors, which leads to a decrease of cell death; activation of cyclic AMP-responsive element-binding protein and Akt via stimulation of the soluble guanylate cyclase-cyclic GMP-protein kinase G pathway; and generation of biliverdin, a precursor of bilirubin, which acts as an antioxidant and antinitrosive molecule, through the induction of the activity of heme oxygenase 1 (10).However, NO can act as a pathophysiological agent because it is associated with hypertension, diabetes, and heart failure among other pathologies (8). In the central nervous system, high amounts of NO inhibit mitochondrial cytochrome oxidase in neurons, causing them to depolarize and to release glutamate and ultimately to die by excitotoxicity via N-methyl-D-aspartate receptors (11,12). NO can also react with superoxide anions and form peroxynitrite, which detains strong oxidant properties and can damage cellular components when protein nitration takes place (10).

Neuropeptide Y (NPY) is one of the most abundant and widely distributed neuropeptides in the mammalian central nervous system (CNS). An overview of the distribution of the G-protein coupled NPY receptor family (Y(1), Y(2), Y(4), Y(5) receptors) in the brain is described. The coexistence of NPY with other neurotransmitters and its wide distribution in several brain areas predict the high importance of NPY as a neuromodulator. Thus, the effect of NPY on the release of several neurotransmitters such as glutamate, gamma-aminobutyric acid (GABA), norepinephrine (NE), dopamine, somastotatin (SOM), serotonin (5-HT), nitric oxide (NO), growth hormone (GH) and corticotropin releasing factor (CRF) is reviewed. A neuroprotective role for NPY under physiological conditions and during hyperactivity such as epileptic-seizures has been suggested. We have shown previously that NPY inhibits glutamate release evoked from hippocampal nerve terminals and has a neuroprotective effect in rat organotypic hippocampal cultures exposed to an excitotoxic insult. Moreover, changes in NPY levels have been observed in different pathological conditions such as brain ischemia and neurodegenerative diseases (Huntington's, Alzheimer's and Parkinson's diseases). Taken together, these studies suggest that NPY and NPY receptors may represent pharmacological targets in different pathophysiological conditions in the CNS.

Herein, we report the use of retinoic acid-loaded polymeric nanoparticles as a potent tool to induce the neuronal differentiation of subventricular zone neural stem cells. The intracellular delivery of retinoic acid by the nanoparticles activated nuclear retinoic acid receptors, decreased stemness, and increased proneurogenic gene expression. Importantly, this work reports for the first time a nanoparticle formulation able to modulate in vivo the subventricular zone neurogenic niche. The work further compares the dynamics of initial stages of differentiation between SVZ cells treated with retinoic acid-loaded polymeric nanoparticles and solubilized retinoic acid. The nanoparticle formulation developed here may ultimately offer new perspectives to treat neurodegenerative diseases.

No abstract